$QQQI

Nearly All of QQQI’s Yield Was Return of Capital, Not Income. Here Is What That Does to Your Cost Basis

NEOS Nasdaq-100 High Income ETF (QQQI) reported that 94.45% of its June 2024 payout was return of capital (ROC), reducing investors' cost basis. This affects future capital gains taxes. QQQI generates income by selling call options on the Nasdaq-100 index. The fund had $13.11 billion in net assets as of June 30, 2026, and its latest monthly distribution was $0.6339 per share.

Original reporting
Published Oct 3, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nearly All of QQQI’s Yield Was Return of Capital, Not Income. Here Is What That Does to Your Cost Basis — source image
Decision brief

The 30-second read

$QQQIBearishLow
01

Why it matters

Investors must adjust cost basis, potentially increasing capital gains tax on future sales, which could dampen demand.

02

Market read

Tax treatment insight may shift allocation among income‑focused ETFs, especially for taxable investors seeking after‑tax yields.

03

What to watch

The ROC classification stems from options‑income tax rules, not fund performance; the fund's capital base remains intact.

Relevance 5/10Novelty 5/10Timing: post‑filing, no immediate trade window

Background

QQQI is a Nasdaq‑100 high‑income ETF that writes call options to generate cash flow. The filing discussed is IRS Form 8937 for FY ending 5/31/2025.

Company-level read

Ticker impact

$QQQIBearishMedium confidence
Context

The article reveals that 94%+ of QQQI's recent distribution is classified as return of capital, altering investors' cost basis and future tax treatment.

Expected impact

likely pressure as the market prices in lower effective yield

Evidence & confidence

Investors focused on taxable income may sell or avoid the ETF, while IRA holders are less affected.

Market effects

Highlights tax‑efficiency considerations for income‑focused ETFs in the broader equity income sector.

U.S. investors may re‑allocate to lower‑tax‑impact funds, modest effect on overall market.

Limited to U.S. taxable investors; minimal global impact.

Counterpoint

Tax‑advantaged accounts (IRAs) still benefit from the ROC feature, making QQQI attractive for long‑term holders.

Key entities

  • NEOS Investments

    Manager of QQQI and filer of the IRS Form 8937.

  • Invesco QQQ Trust

    Low‑fee Nasdaq‑100 ETF cited as a comparison.

Related articles

$AMZNMed

Amazon’s $8B Nvidia Chip Leaseback Deal [2026]

Amazon is reportedly in talks to lease back $8B worth of Nvidia Grace Blackwell chips from a financing vehicle, moving them off its balance sheet. The deal, if finalized, would involve an SPV issuing debt to investors and leasing the chips back to Amazon for AWS data centers. Both companies have not confirmed the deal, and details are still under discussion. The structure is part of a broader trend of tech firms using off-balance-sheet financing for AI infrastructure.

$BACMed

Bank of America (BAC) Personal Retirement Strategy Tops $100 Billion In Assets

Bank of America (BAC) reports its Personal Retirement Strategy program has surpassed $100 billion in assets under management, driven by digital tools combining managed portfolios with personalized retirement planning. This milestone reflects strong client uptake and potential for fee-based revenue growth, aligning with the bank's broader digital engagement strategy.

$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.